## **Core Concept**
Amphotericin B is a polyene antifungal medication used to treat serious fungal infections. Its primary mechanism of action involves binding to ergosterol in fungal cell membranes, disrupting membrane integrity. However, it can also interact with cholesterol in human cell membranes, leading to toxicity.

## **Why the Correct Answer is Right**
The correct answer, **C. Liposomal formulation**, is right because encapsulating amphotericin B in liposomes reduces its interaction with human cell membranes, thereby decreasing its toxicity, particularly nephrotoxicity. Liposomal formulations alter the drug's distribution, allowing higher doses to be administered with lower toxicity.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because there is no established method or formulation listed that effectively reduces amphotericin B toxicity by simple alteration of administration route or common excipients.
- **Option B:** This option is incorrect as there is no widely recognized formulation or strategy by this letter provided that effectively mitigates amphotericin B toxicity.
- **Option D:** This option is incorrect because, similar to option A, there's no standard approach or formulation provided here that effectively reduces amphotericin B toxicity.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the use of **liposomal amphotericin B** significantly reduces the risk of nephrotoxicity compared to the conventional formulation. This is a critical consideration in patients with pre-existing renal impairment or those at high risk of kidney injury.

## **Correct Answer:** . Liposomal formulation